News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Sets Aside $491 Million for Rapamune Marketing


11/2/2012 6:49:33 AM

Two years ago, a federal judge approved a move by the US Justice Department to intervene – or join – a widely publicized whistleblower lawsuit that accused Wyeth of illegally marketing the Rapamune kidney transplant drug for unapproved uses and for targeting African-Americans, a high-risk patient group. Now, Pfizer – which bought Wyeth in 2009 – has set aside $491 million in connection with an agreement-in-principle with the feds (see this).

There have been many off-label allegations, but this particular lawsuit prompted considerable interest because of the sensational accusation that Wyeth targeted African-Americans. Wyeth managers were allegedly aware of limited data for Rapamune use in high-risk patients, but Wyeth deliberately targeted two hospitals with mostly African-American patients – Philadelphia’s Einstein Medical Center and New York’s SUNY Downstate Medical Center.

Read at Pharmalot

comments powered by Disqus
Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES